Skip to main content
. 2013 Jan 25;3:6. doi: 10.3389/fonc.2013.00006

Table 1.

Pharmacological strategies for targeting GBM-SCs.

Strategy Targets Reference
Canonical pathway inhibitors EGFR, TGF-β, c-MET, PI3K/Akt, STAT3 Eyler et al. (2008), Bleau et al. (2009), Sherry et al. (2009), Anido et al. (2010), Jin et al. (2011), Joo et al. (2012)
Self-renewal pathway inhibitors Sonic Hedgehog, Notch Bar et al. (2007), Fan et al. (2010)
Differentiation-inducing agents Retinoic acid, BMPs, IFN-β Piccirillo et al. (2006), Yuki et al. (2009), Ying et al. (2011), Tate et al. (2012)
CSC-microenvironment disrupting agents HIFs, VEGF/VEGFR axis, Notch Li et al. (2009), Zhu et al. (2011), Hamerlik et al. (2012)
DNA damage response Chk1 and Chk2 Bao et al. (2006b), Ropolo et al. (2009)